https://doi.org/10.1140/epje/s10189-025-00503-5
Regular Article - Living Systems
On degree-dependent topological study of line graph of some antiviral COVID-19 drugs
Department of Mathematics, Institute of Science, Banaras Hindu University, 221005, Varanasi, Uttar Pradesh, India
Received:
25
February
2025
Accepted:
24
June
2025
Published online:
14
July
2025
A topological index is a numerical value that correlates with a chemical structure. A degree-based topological index of drug molecular structures is beneficial for researchers investigating in the fields of medicals and pharmaceuticals because it is significant for testing the physicochemical properties of drugs. Graph theory has proven to be quite useful in this field of study. Graph analysis reveals insights into chemical structures. In physical chemistry, a line graph has multiple applications. This article focuses on the topological characterization of a line graph for antiviral COVID-19 drugs, namely Nirmatrelvir, Molnupiravir, Thalidomide, Theaflavin, Remdesivir, Ritonavir, Chloroquine, Hydroxychloroquine, Arbidol and Lopinavir. The computation of degree-based topological indices is carried out using their M-polynomials. Numerical values of topological indices of line graphs and geometric representations of the polynomials are shown graphically. A comparative study between the obtained values of the line graph and the values of an actual graph is presented through numerical and graphical representation. Furthermore, we conduct a QSPR analysis between the degree-based topological indices of the line graph of certain COVID-19 drugs and their physicochemical properties using curvilinear regression models. A comparison is made between the squared correlation coefficients derived from our curvilinear regression models and those obtained from earlier research. These findings may aid the applicability of newly developed drugs of similar kind, in predicting their physicochemical properties and in improving the associated QSPR studies and hence pave a way to improve treatments against the COVID-19 disease.
Copyright comment Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
© The Author(s), under exclusive licence to EDP Sciences, SIF and Springer-Verlag GmbH Germany, part of Springer Nature 2025
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
